DaTscan

Phase 3Small molecule

NNavidea Biopharmaceuticals

DaTscan is one of 52 small molecule programs targeting Lewy body dementia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lewy Body DementiaActive, not recruiting

Parkinson DiseaseActive, not recruiting

Lewy Body DementiaPhase 3

Active, not recruiting

Parkinson DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Parkinson Disease

#DrugCompanyPhaseTrials

Vesicare

Astellas

Phase 3

1 2

Byetta

Mirapex

3 4

Allegra

CChattem

Phase 3

1 5

Avicel

SSanthera Pharmaceuticals

Phase 3

1 6

Xifaxan

SSalix

Phase 3

—7

Wakix

HHarmony Biosciences Management, Inc.

Phase 3

—8

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 3

—9

Aquasol E

NNational Eye Institute (NEI)

Phase 3

—10

Levodopa/carbidopa

Orion Corporation, Orion Pharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Parkinsonian Syndromes1 trial

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Withdrawn·NNavidea Biopharmaceuticals·Phase 3·NCT01950468

Systemic1 trial

Systemic Synuclein Sampling Study (S4)

Completed·MMichael J. Fox Foundation for Parkinson's Research··NCT02572713·80 enrolled

Parkinson disease1 trial

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

Completed·—·Phase 2·NCT01141023·952 enrolled

Imaging1 trial

Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

Completed·MMolecular NeuroImaging·Phase 1·NCT03058965·12 enrolled

Lewy body dementia1 trial

Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia

Completed·GGE Healthcare·Phase 3·NCT00209456·326 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for DaTscan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DaTscan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DaTscan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Navidea Biopharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNavidea Biopharmaceuticals

DaTscan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Parkinsonian Syndromes1 trial

Systemic1 trial

Parkinson disease1 trial

Imaging1 trial

Lewy body dementia1 trial

References

Drug Info

Quick Facts

Related News